Neomend Inc., an Irvine medical products maker, said Wednesday that it has raised $30 million in a fourth round of funding.
Clarus Ventures, a firm with offices in San Francisco and Boston, led the funding with a $17 million contribution.
Other investors include Bay Area firms Prospect Venture Partners and Sanderling Ventures.
Neomend makes sealants and products that prevent internal scarring during surgeries.
Neomend has raised around $55 million in venture capital since 2007, according to venture capital sources. That makes it one of the county’s better-funded startups.
Its current funding is one of the largest recent venture investments in a local company.
Neomend, which was founded in 1999, said in a statement that the funding will help move it toward breaking even on cash flow.
Earlier this month, Neomend said it received premarket approval from the Food and Drug Administration for its ProGel pleural air leak sealant, which is used in lung surgeries.
Neomend said that it received the approval after a multicenter, 161-patient clinical study.
The company said it added device executive David Clapper to its board of directors in conjunction with the investment.
Clapper was most recently chief executive of SurgRx Inc., a Bay Area company that was bought by Johnson & Johnson’s Ethicon Endo-Surgery unit in 2008.
